Please login to the form below

Not currently logged in
Email:
Password:

IQVIA

This page shows the latest IQVIA news and features for those working in and with pharma, biotech and healthcare.

PMEA 2019: Recognising excellence in improving patient outcomes

PMEA 2019: Recognising excellence in improving patient outcomes

Takeda also won in three other categories: Excellence in Collaboration and Partnerships for A Gut Reaction with support from IQVIA, Excellence in Patient Education and Support for NINLARO Patient Support Programme

Latest news

More from news
Approximately 12 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • BRIC markets BRIC markets

    Research by the IQVIA Institute for Human data science suggests spending on medicines in BRIC nations has slowed down. ... year. But, despite the slowing growth rates the BRIC markets still hold potential, according to Michael Kleinrock, IQVIA lead

  • It started with a miss It started with a miss

    first year, IQVIA’s most recent analysis reveals that fewer than 10% of pharma’s launches can be categorised as ‘excellent’. ... IQVIA says that more than 80% of launches don’t improve on their first six months, with less than 10% improving

  • Growing up as a patient is hard to manage Growing up as a patient is hard to manage

    Find out more about these potential solutions by visiting www.iqvia.com or emailing clare.moloney@iqvia.com to request a copy of our recent White Paper: ‘Growing up as a ... Clare Moloney is Programme Insights and Design Lead, Medical and Patient

  • Novel endpoints in the digital age Novel endpoints in the digital age

    Industry’s desire for greater patient-centricity is driving the change, according to Jean Paty, vice president of patient-centred endpoints at IQVIA. ... A closer look. New technologies are also being used to look at established endpoints in a novel way

  • Rethinking trials: the pros and cons of protocol amendments Rethinking trials: the pros and cons of protocol amendments

    Science and Strategy unit at IQVIA. ... Flexibility. Protocol amendments provide drug developers with the flexibility needed to conduct scientifically robust research, said Jenny Fam, Associate Director, Global Regulatory Affairs, IQVIA.

More from intelligence
Approximately 3 fully matching, plus 14 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Women in science
The role of women in science and technology
Why the lack of female leaders in pharma and life sciences is a problem that still needs to be fixed...
Maria Dahl
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
China secures a place at the forefront of innovative medicine...
Virtual Research Grants Submission and Approval Program
Impetus Digital summarizes how a client established an independent grant review committee and a virtual grant submission and approval program, without having to travel and meet in person....

Infographics